Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$114.28 USD

114.28
166,528

+0.33 (0.29%)

Updated Oct 7, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Arpita Dutt headshot

5 Drug Stocks in Focus on World MS Day

Life with MS -- this world MS day, here's a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market.

    Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada

    Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.

      Kite Pharma Cancer Drug BLA Gets Priority Review Status

      Kite Pharma, Inc. (KITE) announced that its biologics license application (BLA) for its experimental CAR-T therapy, axicabtagene ciloleucel has been accepted for priority review by the FDA.

        Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline

        We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.

          Novartis (NVS) Reports Positive Data on Ultibro Breezhaler

          Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.

            Madeleine Johnson headshot

            Here's Why Alexion Pharma (ALXN) Stock is Sinking Today

            On Tuesday, shares of Alexion Pharmaceuticals Inc. (ALXN) are sinking, down over about 8.5% in mid-morning trading after the company announced a series of changes to its executive team.

              Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion

              Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.

                Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

                Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

                  Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls

                  Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.

                    Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates

                    Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure.

                      Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat

                      Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.

                        Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat

                        Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.

                          AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected

                          AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.

                            Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

                            Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.

                              Is Endo (ENDP) Poised for a Beat This Earnings Season?

                              Endo International plc (ENDP) is scheduled to report first-quarter 2017 results on May 9, before the opening bell.

                                Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss

                                Ophthotech Corporation (OPHT) reported first-quarter 2017 loss of $1.20 per share, narrower than the Zacks Consensus Estimate of a loss of $1.31 but wider than the year-ago loss of $1.03

                                  Can Ligand (LGND) Spring a Surprise this Earnings Season?

                                  Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

                                    Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?

                                    We expect Conatus Pharmaceuticals Inc. (CNAT) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

                                      Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline

                                      Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .

                                        The Medicines Company (MDCO) Q1 Loss Wider Than Expected

                                        The Medicines Company (MDCO) reported loss $1.44 per share, wider than the Zacks Consensus Estimate of a loss of $1.13.

                                          What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?

                                          Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.

                                            Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales

                                            Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.

                                              Arpita Dutt headshot

                                              Key Factors to Look Out for in Celgene's (CELG) Q1 Results

                                              Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.

                                                Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS

                                                As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.

                                                  What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?

                                                  GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.